A Phase 3 interventional study of recombinant human growth hormone and recombinant human growth hormone in Childhood-onset Growth Hormone Deficiency and Pituitary Dwarfism, sponsored by EMD Serono. Completed at 9 sites in United States. Open to participants aged 13 Years to 25 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 40th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 3rd registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 13 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 1st registered.
Merck KGaA, Darmstadt, Germany’s Dwarfism, Pituitary studies by the year they started, since 2003.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 13 in Dwarfism, Pituitary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.
This is a phase IIIb, prospective, multicenter, randomised, open label study to determine the safety and efficacy of two different dose regimens of r-hGH with a dose escalation scheme. Screening assessments must be completed 30 days prior to SD1 (Study Day 1). Eligible subjects ages 13 to 25 years will be randomised in equal allocation in a 1:1 ratio to one of two treatment groups (30 subjects/group). Daily subcutaneous injections will be self-administered or received from a designated individual using cool.click™, the needle-free growth hormone (GH) delivery device. The study consists of three periods: screening (up to 30 days prior to Study Day 1), active treatment (up to 24 weeks), and follow-up (4 week safety evaluation after the last dose of study medication).
Each subject will be required to complete a daily treatment diary to assess dosing compliance, adverse events, and concomitant medications. Each subject will receive one treatment diary at SD1, weeks 8, 12, and 24. Subjects will be required to record daily diary entries that will capture dosing compliance, adverse events, and concomitant medications. Depending upon treatment allocation and subject tolerability, dose titration will be increased as follows:
Scheduled study visits include screening, baseline, and weeks 8, 12, and 24. Dosage adjustments will be based on subject tolerability and telephone assessments from study drug initiation through week 6. Trunk fat will be measured at SD1, weeks 12 and 24 (or early termination visit). Routine clinical laboratory assessments (hematology, blood chemistries, and urinalysis) will be performed pre-treatment (-30 to -1 SD1) and post-treatment on week 24 (or early termination visit). Special laboratory assessments include the central analysis of lipid panel, fasting insulin, fasting glucose, insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), free thyroxine (T4) , total T4, C-reactive protein (CRP). Physical exams will be performed at screening, weeks 12 and 24. Safety evaluations will occur during scheduled study visits, through telephone assessments, and by the review of adverse events and concomitant events on the subject treatment diary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The day of entry or Study Day 1 is defined as the first day of study treatment. To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria within 30 days prior to Study Day 1.
Exclusion Criteria:
To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Biological: recombinant human growth hormone
0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Biological: recombinant human growth hormone
0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Also known as: Saizen, r-hGH, cool click
0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Also known as: Saizen, r-hGH, cool click
Percent Change From Baseline to Week 24 in Trunk Fat
Time frame: Baseline to Week 24
Percent Change From Baseline to Week 24 in Lean Body Mass
Time frame: Baseline to Week 24
Percent Change From Baseline to Week 24 in Total Body Fat
Time frame: Baseline to Week 24
Percent Change From Baseline to Week 24 in Limb Fat
Time frame: Baseline to Week 24
Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio
Time frame: Baseline to Week 24
Study Initiation Date: 06 Jan 2005 (date of first subject, first dose) Study Completion Date 11 Jun 2006 (date of last subject, last visit) 19 study centres in the United States received IRB approval to participate in this study; 13 of the centres enrolled at least one subject into the study.
| Milestone | Standard Dose Group | High Dose Group |
|---|---|---|
| Started | 15 | 16 |
| Completed | 13 | 12 |
| Not completed | 2 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Stopped taking study drug | 1 | 1 |
| Withdrew: Non-compliant | 0 | 1 |
| Withdrew: Could not commit time for study | 1 | 1 |
| percent change | Standard Dose Group | High Dose Group |
|---|---|---|
| Percent Change From Baseline to Week 24 in Trunk Fat | -6.27 ± 12.72 | -8.36 ± 17.69 |
| percent change | Standard Dose Group | High Dose Group |
|---|---|---|
| Percent Change From Baseline to Week 24 in Lean Body Mass | 3.85 ± 4.05 | 7.10 ± 5.02 |
| percent change | Standard Dose Group | High Dose Group |
|---|---|---|
| Percent Change From Baseline to Week 24 in Total Body Fat | -4.62 ± 9.96 | -9.69 ± 10.54 |
| percent change | Standard Dose Group | High Dose Group |
|---|---|---|
| Percent Change From Baseline to Week 24 in Limb Fat | -3.77 ± 8.85 | -11.09 ± 8.97 |
| percent change | Standard Dose Group | High Dose Group |
|---|---|---|
| Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio | -2.86 ± 6.77 | 2.92 ± 16.16 |
Collected over Baseline to Week 28(+/-5 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Dose Group | — | 0/15 (0%) | 13/15 (86.7%) |
| High Dose Group | — | 1/16 (6.3%) | 14/16 (87.5%) |
| Event | Standard Dose Group | High Dose Group |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/15 | 1/16 |
| Event | Standard Dose Group | High Dose Group |
|---|---|---|
| HeadacheNervous system disorders | 6/15 | 6/16 |
| Upper respiratory tract infectionInfections and infestations | 4/15 | 3/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/15 | 0/16 |
| NasopharyngitisInfections and infestations | 1/15 | 3/16 |
| SinusitisInfections and infestations | 0/15 | 3/16 |
| DysmenorrhoeaReproductive system and breast disorders | 2/15 | 1/16 |
| Injection site bruisingGeneral disorders | 2/15 | 1/16 |
| Back painMusculoskeletal and connective tissue disorders | 0/15 | 2/16 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 2/16 |
| Abdominal pain upperGastrointestinal disorders | 1/15 | 1/16 |
| Age Continuous(years) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 17.4 ± 1.8 | 18.1 ± 1.9 | 17.8 ± 1.9 |
| Sex: Female, Male(Participants) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 10 | 10 | 20 |
| Region of Enrollment(participants) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| United States | 15 | 16 | 31 |
| Lean body mass(kg) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 44.03 ± 11.09 | 44.38 ± 12.98 | 44.21 ± 11.90 |
| Limb fat(kg) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 11.47 ± 5.49 | 12.92 ± 9.28 | 12.22 ± 7.59 |
| Total body fat(kg) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 24.02 ± 10.81 | 25.11 ± 18.29 | 24.58 ± 14.90 |
| Trunk fat(kg) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 11.73 ± 5.58 | 11.40 ± 9.09 | 11.56 ± 7.47 |
| Trunk to limb fat ratio(ratio) | Standard Dose Group | High Dose Group | Total |
|---|---|---|---|
| Mean | 1.05 ± 0.29 | 0.87 ± 0.17 | 0.96 ± 0.25 |
The record gives a start of Jan 2005, a primary completion of Jun 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone